 |
|
What's New
| April 2008 |
New Life for Children with Liver Failure
If a child suffers from a serious liver disorder, treatment by a multidisciplinary center with vast medical and surgical experience can make the difference between an excellent or poor quality of life, or between life and death. At the NewYork-Presbyterian/Columbia Center for Liver Disease and Transplantation, outcomes far surpass the national average, with 92% of children surviving at one year, 89% surviving at two years, and 88% surviving at three years after liver transplantation. But short-term survival is not the goal. If a child lives only one or two years, that is not a successful transplant. Our goal is for every child to live a normal life well into adulthood. |
| April 2008 |
Preventing and Treating Adult Liver Disease
The Center for Liver Disease and Transplantation offers a full spectrum of services to patients suffering from all forms of liver disease, from walk-in office consultations, to antiviral treatment for Hepatitis C and Hepatitis B, to liver transplantation.
In a trend that reflects the rising obesity epidemic, physicians at the center are seeing increasing numbers of patients with non-alcoholic fatty liver disease, a condition associated with obesity.
While non-alcoholic fatty liver disease is clearly on the rise, undetected viral hepatitis C infection accounts for about 50% of the center's patients with chronic liver disease.
Alcoholism accounts for the next largest group of patients at the center, which is noted for its comprehensive, multidisciplinary treatment program. |
| March 2008 |
On March 27, Fox Business ran a Schering-Plough Corporation press release regarding the U.S. Food and Drug Administration approval of label revisions for peginterferon alfa-2b and ribavirin, as a combination therapy for chronic hepatitis C. Robert S. Brown Jr., MD, MPH, was co-principal investigator in the study leading to the label revision, WIN-R. The release was picked up by the Biloxi Sun Herald, and CNN/Money. |
| November 2007 |
 Robert S. Brown, Jr., MD |
| 2007 |
Multimodality Approach Improves Outcomes in Hepatocellular Carcinoma
With nationally and internationally recognized authorities in established modalities as well as experimental techniques, the treatment team for hepatocellular carcinoma and hilar cholangiocarcinoma at the Center for Liver Disease and Transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center is setting new standards for patient outcomes—including long-term survival—in resection, adjuvant therapies, and transplantation. |
| 2007 |
New Drugs, Dosing Highlight New Approaches to Hepatitis C
The Center for the Study of Hepatitis continues to be actively involved in both clinical and basic science research in an effort to identify new treatments for patients infected with the hepatitis C virus (HCV).
A multidisciplinary approach is central to efforts at the Center, which is a collaborative endeavor of Weill Cornell clinicians and researchers at NewYork-Presbyterian Hospital along with colleagues at NewYork-Presbyterian Hospital/Columbia University Medical Center and researchers at Rockefeller University. |
| 2007 |
Liver Transplantation: Better Preservation of Donor Organs May Enable More Transplants
James V. Guarrera, MD |
As advanced as the field of organ transplantation has become, several important challenges remain.
Of these, the availability of donor organs stands paramount.
Among those with end stage liver disease, over 17,000 patients wait for a donated liver every year in the U.S., but fewer than 6000 receive one, and about 1800 people die while on the waiting list.
As a result, researchers are avidly working to find ways to safely use as many potential donor organs as possible, including organs that once may have been considered "imperfect." |
| 2006 |
Living Donor Liver Transplantation Saves Lives
At this time there are eight patients on the waiting list for every available liver — and many patients are considered too sick or too old to even get a place on the list.
To address this serious shortage, the Center for Liver Disease and Transplantation (CLDT) is pioneering methods of increasing access to liver transplantation.
Living donor liver transplantation offers one solution.
|
| May 2006 |
Largest U.S. Hepatitis C Trial Provides Insight into Optimizing Treatment for Patients
Dr. Robert Brown is Co-Principal Investigator of the WIN-R trial, the largest hepatitis C study ever conducted in U.S. patients.
The community-based study which involved more than 4,900 patients at 225 centers across the United States, showed significantly better outcomes with weight-based dosing.
The study findings were reported at the Digestive Diseases Week (DDW) annual meeting, May 20-25, 2006, at the Los Angeles Convention Center.
Dr. Brown and the study's Principal Investigator, Dr. Ira Jacobson of Weill Medical College of Cornell University, are co-directors of New York-Presbyterian Healthcare System's Liver Clinical Trials Network (LCTN).
Click here to read the press release on study presentation at the Digestive Diseases Week. |
| February 2003 |
Dr. Brown Presents First Data on Living Donor Liver Transplant
Procedure shown to be safe for donors and recipients
Robert S. Brown, Jr., MD, MPH is the principal author of an article entitled "A Survey of Liver Transplantation from Living Adult Donors in the United States," published as a Special Article in the February 27, 2003 issue of the New England Journal of Medicine.
The article is the first to present comprehensive data on adult to adult living donor liver transplantation (LDLT) in this country, with responses from 84 of the 122 programs now doing LDLT.
Those 84 centers performed more than 90 percent of all cadaveric liver transplants (transplants that use organs harvested from someone who has died) in the U.S. in 1999 and 2000.
Columbia University Medical Center has one of the nation's most active and outstanding living donor liver transplant programs.
|
 | |
|
